irinotecan has been researched along with Rupture in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angelopoulos, S; Despoudi, K; Kanellos, D; Koliakos, G; Lazaridis, C; Mantzoros, I; Pramateftakis, MG; Raptis, D; Zaraboukas, T | 1 |
| Inai, K; Kishi, S; Morinaga, K; Naiki, H; Tsutani, H; Ueda, T | 1 |
2 other study(ies) available for irinotecan and Rupture
| Article | Year |
|---|---|
Intraperitoneally administered irinotecan with 5-fluorouracil impair wound healing of colonic anastomoses in a rat model: an experimental study.
Topics: Anastomosis, Surgical; Anastomotic Leak; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon; Fluorouracil; Hydroxyproline; Irinotecan; Male; Neovascularization, Physiologic; Pressure; Rats; Rats, Wistar; Rupture; Tissue Adhesions; Wound Healing | 2011 |
Hepatic tumor rupture following effectual treatment with irinotecan in a patient with highly refractory malignant lymphoma.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Fatal Outcome; Humans; Irinotecan; Liver; Liver Neoplasms; Lymphoma, B-Cell; Male; Middle Aged; Rupture; Tumor Lysis Syndrome | 1999 |